ORGN

CEO John Bissell discussed product development progress with new PET cap designs, distribution partnerships like HP Embelligens, and strategic review for value creation. CFO Matt Plavin talked about financial position, updated EBITDA breakeven timing, balance sheet details, and impairment expense. Also, focus on cap product commercialization and supply chain wind down.

Update on adjusted EBITDA run rate breakeven timing pushed from 2027 to 2028 due to design iteration and customer qualification time; previous sales guidance context.

Discuss the progress of Origin's PET cap product segment, including product development, distribution partnerships, and production capacity build out, but no specific absolute financial figures or revenue contribution percentages provided in detail.

Risks include uncertainty in financing sources leading to operational disruption risk, stock price impact on financing, and impairment of OM1 and OM2 assets.

Q: Frank Mitch with Fermium Research asked about forensic side, strategic review, product performance on shelf, sales expectations.

A: John and Matt responded on inbound interest for Furanix, strategic review progress, product performance on shelf, and sales guidance update. Then Q&A on manufacturing capacity, bottling trials, partnerships, sales timeline and risks